Synonyms: Ivacaftor-D9 | VX-561 | VX561
deutivacaftor is an approved drug
Compound class:
Synthetic organic
Comment: Deutivacaftor (VX-561) is a deuterated analogue of ivacaftor. The principal action of this small molecule is as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that increases CFTR chloride channel opening. Deuteration is a strategy that is used to improve the stability and half-life of small molecule drugs.
|
|
References |
1. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M et al.. (2025)
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med, 13 (3): 256-271. [PMID:39756424] |